|
Treatment for restless legs syndrome |
Wilt TJ, MacDonald R, Ouellette J, Tacklind J, Khawaja I, Rutks I, Butler M, Fink HA |
|
|
Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Wilt TJ, MacDonald R, Ouellette J, Tacklind J, Khawaja I, Rutks I, Butler M, Fink HA. Treatment for restless legs syndrome. Rockville: Agency for Healthcare Research and Quality (AHRQ). Comparative Effectiveness Review No. 86. 2012 Authors' objectives To review the comparative effectiveness, efficacy, and safety of pharmacologic and nonpharmacologic treatments for RLS. Authors' conclusions Compared to placebo, dopamine agonists and alpha-2-delta ligands reduce RLS symptoms and improve patient-reported sleep outcomes and disease-specific quality of life. Adverse effects of pharmacologic therapies and long-term treatment withdrawals due to adverse effects or lack of efficacy are common. Long-term effectiveness as well as applicability for adults with milder or less frequent RLS symptoms, individuals with secondary RLS, and children is unknown. Indexing Status Subject indexing assigned by CRD MeSH Restless Legs Syndromes Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence AHRQ, Center for Outcomes and Evidence Technology Assessment Program, 540 Gaither Road, Rockville, MD 20850, USA Email: AHRQTAP@ahrq.hhs.gov AccessionNumber 32013000765 Date abstract record published 25/10/2013 |
|
|
|